BRAF mutations, which are detected in 1–2% of patients with NSCLC, with the most common resulting in the substitution of glutamate with valine at codon 600 (V600E), have become a promising therapeutic target [75]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.